See why Zacks Has a Huge Price Target! ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏
_You are receiving this email because you are subscribed to MORNING
WATCHLIST FROM BEHIND THE MARKETS. If you no longer wish to receive
these partner emails, please unsubscribe
[[link removed]]
here. This message is from Huge Alerts._
-------------------------
[BSEM] [[link removed]]
Bio Stem Technologies Accelerates Into 2026 With Transformative
Acquisition, Seven Straight Profitable Quarters, and Entry into
Advanced and Acute Wound Care Markets!
BioStem Technologies (OTCQB: BSEM)
[[link removed]] is emerging as one of the most
compelling small-cap MedTech companies as 2026 begins. The company
just completed the acquisition of BioTissue Holdings’ surgical and
wound care business, instantly expanding its footprint into
hospital-based, acute, and surgical wound care.
With established product lines like Neox® and Clarix®, a nationwide
sales force, and key GPO contracts, BioStem is now positioned to
capture a $300–$350 million addressable market, spanning chronic and
acute wound care, burns, and soft-tissue repair.
Zacks Small Cap Research has assigned BSEM a $25.50 price target,
highlighting confidence in the company’s profitable growth, clinical
validation, and expanding market presence.
Coupled with seven consecutive profitable quarters, strong gross
margins of 88.5%, and $16 million in cash post-acquisition, BSEM is
demonstrating operational excellence rarely seen in small-cap
regenerative medicine.
Backed by clinically validated BioREtain® technology, FDA-level
studies, and a potential Nasdaq uplisting in mid-2026, BSEM is gaining
traction with both institutional investors and healthcare providers.
Discover why BSEM is setting the standard for profitable, clinically
proven MedTech growth in 2026 [[link removed]]
We are issuing this disclosure in compliance with Section 17(b) of the
Securities Act, which requires us to disclose any compensation
received or expected to be received in cash or in kind in connection
with the purchase or sale of any security.
We would like to inform you that we have received or expect to receive
compensation in connection with the purchase or sale of the securities
of BioStem Technologies Inc. (OTC: BSEM) . The compensation consists
of up to $6,500 and was received/will be received from Sideways
Frequency.
This communication should not be considered as an endorsement of the
securities of BioStem Technologies Inc. (OTC: BSEM) and we are not
responsible for any errors or omissions in any information provided
about the securities of BioStem Technologies Inc. (OTC: BSEM) by Huge
Alerts.
We encourage you to conduct your own due diligence and research before
making any investment decisions. You should also consult with a
financial advisor before making any investment decisions.
This disclosure is made as of 02/02/2026.
Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431
Copyright © 2024 Behind the Markets, LLC, All rights reserved.
You're receiving this email as part of your subscription to Behind the
Markets. For more information about our privacy practices, please
review our Privacy Policy
[[link removed]]
or our Legal Notices.
[[link removed]]
Behind the Markets
[[link removed]]
_You are receiving this email because you are subscribed to Morning
Watchlist from Behind the Markets. If you no longer wish to receive
these partner emails, please unsubscribe here
[[link removed]]._
TODAY'S BONUS CONTENT: Buy AES Immediately
[[link removed]]
